BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

968 related articles for article (PubMed ID: 30840262)

  • 1. Downregulation of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by PI3K-AKT signaling pathways and indicates good prognosis.
    Liu ZB; Wang JA; Lv RQ
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1418-1427. PubMed ID: 30840262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142.
    Zhang L; Zhao G; Ji S; Yuan Q; Zhou H
    Med Sci Monit; 2020 Mar; 26():e921594. PubMed ID: 32155139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p.
    Song L; Zhou Z; Gan Y; Li P; Xu Y; Zhang Z; Luo F; Xu J; Zhou Q; Dai F
    J Cell Biochem; 2019 Jun; 120(6):9656-9666. PubMed ID: 30548308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long noncoding RNA ABHD11-AS1 predicts the prognosis of pancreatic cancer patients and serves as a promoter by activating the PI3K-AKT pathway.
    Qiao X; Lv SX; Qiao Y; Li QP; Ye B; Wang CC; Miao L
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8630-8639. PubMed ID: 30575903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of TBRG4 suppresses proliferation, invasion and promotes apoptosis of osteosarcoma cells by downregulating TGF-β1 expression and PI3K/AKT signaling pathway.
    Huang F; Zhou P; Wang Z; Zhang XL; Liao FX; Hu Y; Chang J
    Arch Biochem Biophys; 2020 Jun; 686():108351. PubMed ID: 32240636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA LINC00628 overexpression inhibits the growth and invasion through regulating PI3K/Akt signaling pathway in osteosarcoma.
    He R; Wu JX; Zhang Y; Che H; Yang L
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5857-5866. PubMed ID: 30280767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of Long Non-Coding RNA NNT-AS1 Correlates with Tumor Progression and Poor Prognosis in Osteosarcoma.
    Ye H; Lin J; Yao X; Li Y; Lin X; Lu H
    Cell Physiol Biochem; 2018; 45(5):1904-1914. PubMed ID: 29518771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA TP73-AS1 promoted the progression of lung adenocarcinoma via PI3K/AKT pathway.
    Liu C; Ren L; Deng J; Wang S
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30541897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role and clinical significance of long noncoding RNA zinc finger E-box-binding homeobox two antisense RNA 1 in promoting osteosarcoma cancer cell proliferation, inhibiting apoptosis and increasing migration by regulating miR-145.
    Zhou Y; Feng D; Gu X; Gao A; Liu Y
    Anticancer Drugs; 2021 Feb; 32(2):168-177. PubMed ID: 32826416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA RUSC1-AS1 promotes osteosarcoma progression through regulating the miR-340-5p and PI3K/AKT pathway.
    Tong CJ; Deng QC; Ou DJ; Long X; Liu H; Huang K
    Aging (Albany NY); 2021 May; 13(16):20116-20130. PubMed ID: 34048366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA MALAT1 Promotes Cancer Metastasis in Osteosarcoma via Activation of the PI3K-Akt Signaling Pathway.
    Chen Y; Huang W; Sun W; Zheng B; Wang C; Luo Z; Wang J; Yan W
    Cell Physiol Biochem; 2018; 51(3):1313-1326. PubMed ID: 30481748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway.
    Liu G; Zhao X; Zhou J; Cheng X; Ye Z; Ji Z
    Cell Physiol Biochem; 2018; 48(1):371-384. PubMed ID: 30016766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA ADPGK-AS1 regulated cell proliferation, invasion, migration and apoptosis via targeting miR-542-3p in osteosarcoma.
    Luo XF; Wu XJ; Wei X; Wang AG; Wang SH; Wang JL
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8751-8760. PubMed ID: 31696461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lncRNA HNF1A-AS1 is a negative prognostic factor and promotes tumorigenesis in osteosarcoma.
    Cai L; Lv J; Zhang Y; Li J; Wang Y; Yang H
    J Cell Mol Med; 2017 Nov; 21(11):2654-2662. PubMed ID: 28866868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LOXL1-AS1 predicts poor prognosis and promotes cell proliferation, migration, and invasion in osteosarcoma.
    Chen S; Li W; Guo A
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30944201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIX1 reduces the expression of PTEN via activating PI3K/AKT signal to promote cell proliferation and tumorigenesis in osteosarcoma.
    Yu C; Zhang B; Li YL; Yu XR
    Biomed Pharmacother; 2018 Sep; 105():10-17. PubMed ID: 29807230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA FER1L4 induces apoptosis and suppresses EMT and the activation of PI3K/AKT pathway in osteosarcoma cells via inhibiting miR-18a-5p to promote SOCS5.
    Ye F; Tian L; Zhou Q; Feng D
    Gene; 2019 Dec; 721():144093. PubMed ID: 31473323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of long non-coding RNA ITGB2-AS1 inhibits osteosarcoma proliferation and metastasis by repressing Wnt/β-catenin signalling and predicts favourable prognosis.
    Dai J; Xu LJ; Han GD; Jiang HT; Sun HL; Zhu GT; Tang XM
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S783-S790. PubMed ID: 30260245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
    Zheng J; Liu C; Shi J; Wen K; Wang X
    Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA LINP1 functions as an oncogene in endometrial cancer progression by regulating the PI3K/AKT signaling pathway.
    Zhang XH; Li M; Kang YJ; Xie YQ; Cao YX
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6830-6838. PubMed ID: 31486482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.